Please provide your email address to receive an email when new articles are posted on . Men with metastatic castration-resistant prostate cancer had significantly longer OS with docetaxel rechallenge ...

Philadelphia, November 12, 2024 – The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically changed in recent years. However, aside from ...

Shares in CRISM Therapeutics rose 19% to 14p on Tuesday after the AIM-quoted drug delivery company reported positive ...

Three-year median follow-up update of BGB-A317-2002-IIT: A phase 2 study of neoadjuvant tislelizumab plus gemcitabine and cisplatin in patients with cT2–T4aN0M0 muscle-invasive bladder cancer. This is ...

A real-world comparison of two androgen receptor pathway inhibitors (ARPIs) for advanced prostate cancer showed a significant difference in overall survival (OS). Patients with metastatic ...

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis The standard of care for ...

Please provide your email address to receive an email when new articles are posted on . The addition of pyrotinib to trastuzumab and docetaxel improved 4-year OS vs. placebo for patients with ...

A growing array of pharmaceutical options has investigators trying to figure out which drugs and drug combinations are the best to prescribe upfront—and to which patients. Over the past 14 years, ...